Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical predictors of response to single‑agent immune checkpoint inhibitors in chemotherapy‑pretreated non‑small cell lung cancer.
Musaelyan AA, Moiseyenko FV, Emileva TE, Oganesyan AP, Oganyan KA, Urtenova MA, Odintsova SV, Chistyakov IV, Degtyarev AM, Akopov AL, Imyanitov EN, Orlov SV. Musaelyan AA, et al. Among authors: orlov sv. Mol Clin Oncol. 2024 Feb 20;20(4):32. doi: 10.3892/mco.2024.2730. eCollection 2024 Apr. Mol Clin Oncol. 2024. PMID: 38476335 Free PMC article.
Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants.
Mitiushkina NV, Tiurin VI, Iyevleva AG, Kholmatov MM, Filippova EA, Moiseyenko FV, Levchenko NE, Sardaryan IS, Odintsova SV, Lozhkina AM, Volkov NM, Karaseva NA, Moiseyenko VM, Orlov SV, Imyanitov EN. Mitiushkina NV, et al. Among authors: orlov sv. Biochimie. 2018 Nov;154:19-24. doi: 10.1016/j.biochi.2018.07.018. Epub 2018 Jul 30. Biochimie. 2018. PMID: 30071258
Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study.
Orlov SV, Iyevleva AG, Filippova EA, Lozhkina AM, Odintsova SV, Sokolova TN, Mitiushkina NV, Tiurin VI, Preobrazhenskaya EV, Romanko AA, Martianov AS, Ivantsov AO, Aleksakhina SN, Togo AV, Imyanitov EN. Orlov SV, et al. Transl Oncol. 2021 Aug;14(8):101121. doi: 10.1016/j.tranon.2021.101121. Epub 2021 May 21. Transl Oncol. 2021. PMID: 34030112 Free PMC article.
EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts.
Lavdovskaia ED, Iyevleva AG, Sokolenko AP, Mitiushkina NV, Preobrazhenskaya EV, Tiurin VI, Ivantsov AO, Bizin IV, Stelmakh LV, Moiseyenko FV, Karaseva NA, Orlov SV, Moiseyenko VM, Korzhenevskaya MA, Zaitsev IA, Kozak AR, Chistyakov IV, Akopov AL, Volkov NM, Togo AV, Imyanitov EN. Lavdovskaia ED, et al. Among authors: orlov sv. Oncol Res Treat. 2018;41(10):634-642. doi: 10.1159/000491441. Epub 2018 Aug 27. Oncol Res Treat. 2018. PMID: 30145586
Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.
Iyevleva AG, Mitiushkina NV, Karaseva NA, Orlov SV, Volodina LN, Kulikova YE, Lozhkina AM, Ivantsov AO, Tiurin VI, Togo AV, Imyanitov EN. Iyevleva AG, et al. Among authors: orlov sv. J Thorac Oncol. 2014 Apr;9(4):e31-3. doi: 10.1097/JTO.0000000000000106. J Thorac Oncol. 2014. PMID: 24736087 Free article. No abstract available.
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, Ji Y, Dvorkin M, Shi J, Pan Z, Shi J, Wang X, Bai Y, Melkadze T, Pan Y, Min X, Viguro M, Li X, Zhao Y, Yang J, Makharadze T, Arkania E, Kang W, Wang Q, Zhu J; ASTRUM-005 Study Group. Cheng Y, et al. JAMA. 2022 Sep 27;328(12):1223-1232. doi: 10.1001/jama.2022.16464. JAMA. 2022. PMID: 36166026 Free PMC article. Clinical Trial.
138 results